SeLux Diagnostics
Selux Diagnostics is a Boston-based company dedicated to developing precision diagnostics for infectious diseases. Their mission is to deliver personalized diagnostic information to optimize treatment, combat antibiotic-resistant superbugs, and preserve the lifesaving power of antibiotics. They focus on rapid antimicrobial susceptibility testing (AST) using their proprietary Next Generation Phenotyping (NGP) System to improve patient care and address the global health crisis of antimicrobial resistance.
Industries
Nr. of Employees
medium (51-250)
SeLux Diagnostics
Patents
System, method and interface for parallel processing of antimicrobial susceptibility tests using different samples
US-12129510-B2
View DetailsSystem, method and interface for parallel processing of antimicrobial susceptibility tests using different samples
US-11866763-B2
View DetailsAssays for improving automated antimicrobial susceptibility testing accuracy
US-11835523-B2
View Details
System, method and interface for parallel processing of antimicrobial susceptibility tests using different samples
US-12129510-B2
View DetailsSystem, method and interface for parallel processing of antimicrobial susceptibility tests using different samples
US-11866763-B2
View DetailsAssays for improving automated antimicrobial susceptibility testing accuracy
US-11835523-B2
View DetailsProducts
Next-generation phenotyping (NGP) AST system
Integrated diagnostic platform for rapid phenotypic antimicrobial susceptibility testing that includes automated sample preparation, high-density assay panels, and a high-throughput analyzer to provide same-shift results from isolates and positive blood cultures.
Selux Analyzer
An automated clinical microbiology AST analyzer that delivers rapid phenotypic antimicrobial susceptibility testing results with an 86-panel capacity and continuous, random access.
Selux NGP System
A rapid phenotypic antimicrobial susceptibility testing (AST) platform utilizing proprietary 384-well panels, Viability Assays, and Surface Area Assays to deliver fast, accurate, and comprehensive results direct from positive blood culture and isolates.
Selux 384-well panel
A proprietary 384-well antimicrobial susceptibility testing panel that offers extensive bug/drug combinations, precise MICs, doubling dilutions, and control wells.
Selux Separator
The Selux Separator can simultaneously process two positive blood culture samples in under an hour and uses an all-in-one reagent kit that can be stored at room temperature. It isolates the bacterial sample from a positive blood culture bottle, resuspends the bacteria in saline, and delivers an AST-ready McFarland.
Selux Inoculator
The Selux Inoculator automates complex and precise pipetting to prepare 384-well panels for AST, allowing for unique concentrations of each sample to be dispensed in complex patterns.
Next-generation phenotyping (NGP) AST system
Integrated diagnostic platform for rapid phenotypic antimicrobial susceptibility testing that includes automated sample preparation, high-density assay panels, and a high-throughput analyzer to provide same-shift results from isolates and positive blood cultures.
Selux Analyzer
An automated clinical microbiology AST analyzer that delivers rapid phenotypic antimicrobial susceptibility testing results with an 86-panel capacity and continuous, random access.
Selux NGP System
A rapid phenotypic antimicrobial susceptibility testing (AST) platform utilizing proprietary 384-well panels, Viability Assays, and Surface Area Assays to deliver fast, accurate, and comprehensive results direct from positive blood culture and isolates.
Selux 384-well panel
A proprietary 384-well antimicrobial susceptibility testing panel that offers extensive bug/drug combinations, precise MICs, doubling dilutions, and control wells.
Selux Separator
The Selux Separator can simultaneously process two positive blood culture samples in under an hour and uses an all-in-one reagent kit that can be stored at room temperature. It isolates the bacterial sample from a positive blood culture bottle, resuspends the bacteria in saline, and delivers an AST-ready McFarland.
Selux Inoculator
The Selux Inoculator automates complex and precise pipetting to prepare 384-well panels for AST, allowing for unique concentrations of each sample to be dispensed in complex patterns.
Services
Webinars, conference presentations, and educational material focused on rapid AST, breakpoint updates, and antimicrobial stewardship.
Online customer hub, technical help email, and support resources for instrument and assay users.
Guidance and data to help laboratories validate assays and implement current clinical breakpoints.
Webinars, conference presentations, and educational material focused on rapid AST, breakpoint updates, and antimicrobial stewardship.
Online customer hub, technical help email, and support resources for instrument and assay users.
Guidance and data to help laboratories validate assays and implement current clinical breakpoints.
Expertise Areas
- Rapid antimicrobial susceptibility testing
- Direct-from-blood-culture diagnostic workflows
- Assay development and analytical methods for AST
- Clinical and multi-site performance validation
Key Technologies
- Rapid phenotypic AST
- Direct-from-positive-blood-culture testing
- 384-well high-density assay panels
- Viability assays
News & Updates
The FDA has cleared the Selux NGP System for rapid antibiotic susceptibility testing directly from positive blood culture, enhancing the speed and accuracy of diagnostics.
Selux Diagnostics has announced an additional $48 million in funding to support the development and commercialization of their rapid AST platform.
The company received FDA clearance for their Gram-Negative Panel, expanding their diagnostic capabilities.
Selux aims to outsmart bacteria with rapid AST to help prevent the rise of antibiotic resistance and save lives.
This article discusses how rapid AST technologies can significantly improve patient outcomes by providing faster and more accurate susceptibility results.
This article explores the importance of rapid AST in clinical settings, highlighting its benefits in terms of speed, accuracy, and impact on healthcare costs.
The FDA has cleared the Selux NGP System for rapid antibiotic susceptibility testing directly from positive blood culture, enhancing the speed and accuracy of diagnostics.
Selux Diagnostics has announced an additional $48 million in funding to support the development and commercialization of their rapid AST platform.
The company received FDA clearance for their Gram-Negative Panel, expanding their diagnostic capabilities.
Selux aims to outsmart bacteria with rapid AST to help prevent the rise of antibiotic resistance and save lives.
This article discusses how rapid AST technologies can significantly improve patient outcomes by providing faster and more accurate susceptibility results.
This article explores the importance of rapid AST in clinical settings, highlighting its benefits in terms of speed, accuracy, and impact on healthcare costs.